Long-Acting β2-Agonists in Asthma

Enantioselective Safety Studies are Needed

Glenn A. Jacobson, Sharanne Raidal, Morten Hostrup, Luigino Calzetta, Richard Wood-Baker, Mark O. Farber, Clive P. Page, E. Haydn Walters

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Long-acting β2-agonists (LABAs) such as formoterol and salmeterol are used for prolonged bronchodilatation in asthma, usually in combination with inhaled corticosteroids (ICSs). Unexplained paradoxical asthma exacerbations and deaths have been associated with LABAs, particularly when used without ICS. LABAs clearly demonstrate effective bronchodilatation and steroid-sparing activity, but long-term treatment can lead to tolerance of their bronchodilator effects. There are also concerns with regard to the effects of LABAs on bronchial hyperresponsiveness (BHR), where long-term use is associated with increased BHR and loss of bronchoprotection. A complicating factor is that formoterol and salmeterol are both chiral compounds, usually administered as 50:50 racemic (rac-) mixtures of two enantiomers. The chiral nature of these compounds has been largely forgotten in the debate regarding LABA safety and effects on BHR, particularly that (S)-enantiomers of β2-agonists may be deleterious to asthma control. LABAs display enantioselective pharmacokinetics and pharmacodynamics. Biological plausibility of the deleterious effects of β2-agonists (S)-enantiomers is provided by in vitro and in vivo studies from the short-acting β2-agonist (SABA) salbutamol. Supportive clinical findings include the fact that patients in emergency departments who demonstrate a blunted response to salbutamol are more likely to benefit from (R)-salbutamol than rac-salbutamol, and resistance to salbutamol appears to be a contributory mechanism in rapid asthma deaths. More effort should therefore be applied to investigating potential enantiospecific effects of LABAs on safety, specifically bronchoprotection. Safety studies directly assessing the effects of LABA (S)-enantiomers on BHR are long overdue.

Original languageEnglish
Pages (from-to)441-449
Number of pages9
JournalDrug Safety
Volume41
Issue number5
DOIs
Publication statusPublished - May 2018

Fingerprint

Albuterol
Enantiomers
Asthma
Safety
Adrenal Cortex Hormones
Pharmacodynamics
Pharmacokinetics
Bronchodilator Agents
Hospital Emergency Service
Steroids
Formoterol Fumarate
Salmeterol Xinafoate

Cite this

Jacobson, G. A., Raidal, S., Hostrup, M., Calzetta, L., Wood-Baker, R., Farber, M. O., ... Walters, E. H. (2018). Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed. Drug Safety, 41(5), 441-449. https://doi.org/10.1007/s40264-017-0631-1
Jacobson, Glenn A. ; Raidal, Sharanne ; Hostrup, Morten ; Calzetta, Luigino ; Wood-Baker, Richard ; Farber, Mark O. ; Page, Clive P. ; Walters, E. Haydn. / Long-Acting β2-Agonists in Asthma : Enantioselective Safety Studies are Needed. In: Drug Safety. 2018 ; Vol. 41, No. 5. pp. 441-449.
@article{ff019d3f245242078a579b374516a960,
title = "Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed",
abstract = "Long-acting β2-agonists (LABAs) such as formoterol and salmeterol are used for prolonged bronchodilatation in asthma, usually in combination with inhaled corticosteroids (ICSs). Unexplained paradoxical asthma exacerbations and deaths have been associated with LABAs, particularly when used without ICS. LABAs clearly demonstrate effective bronchodilatation and steroid-sparing activity, but long-term treatment can lead to tolerance of their bronchodilator effects. There are also concerns with regard to the effects of LABAs on bronchial hyperresponsiveness (BHR), where long-term use is associated with increased BHR and loss of bronchoprotection. A complicating factor is that formoterol and salmeterol are both chiral compounds, usually administered as 50:50 racemic (rac-) mixtures of two enantiomers. The chiral nature of these compounds has been largely forgotten in the debate regarding LABA safety and effects on BHR, particularly that (S)-enantiomers of β2-agonists may be deleterious to asthma control. LABAs display enantioselective pharmacokinetics and pharmacodynamics. Biological plausibility of the deleterious effects of β2-agonists (S)-enantiomers is provided by in vitro and in vivo studies from the short-acting β2-agonist (SABA) salbutamol. Supportive clinical findings include the fact that patients in emergency departments who demonstrate a blunted response to salbutamol are more likely to benefit from (R)-salbutamol than rac-salbutamol, and resistance to salbutamol appears to be a contributory mechanism in rapid asthma deaths. More effort should therefore be applied to investigating potential enantiospecific effects of LABAs on safety, specifically bronchoprotection. Safety studies directly assessing the effects of LABA (S)-enantiomers on BHR are long overdue.",
author = "Jacobson, {Glenn A.} and Sharanne Raidal and Morten Hostrup and Luigino Calzetta and Richard Wood-Baker and Farber, {Mark O.} and Page, {Clive P.} and Walters, {E. Haydn}",
year = "2018",
month = "5",
doi = "10.1007/s40264-017-0631-1",
language = "English",
volume = "41",
pages = "441--449",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "5",

}

Jacobson, GA, Raidal, S, Hostrup, M, Calzetta, L, Wood-Baker, R, Farber, MO, Page, CP & Walters, EH 2018, 'Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed', Drug Safety, vol. 41, no. 5, pp. 441-449. https://doi.org/10.1007/s40264-017-0631-1

Long-Acting β2-Agonists in Asthma : Enantioselective Safety Studies are Needed. / Jacobson, Glenn A.; Raidal, Sharanne; Hostrup, Morten; Calzetta, Luigino; Wood-Baker, Richard; Farber, Mark O.; Page, Clive P.; Walters, E. Haydn.

In: Drug Safety, Vol. 41, No. 5, 05.2018, p. 441-449.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-Acting β2-Agonists in Asthma

T2 - Enantioselective Safety Studies are Needed

AU - Jacobson, Glenn A.

AU - Raidal, Sharanne

AU - Hostrup, Morten

AU - Calzetta, Luigino

AU - Wood-Baker, Richard

AU - Farber, Mark O.

AU - Page, Clive P.

AU - Walters, E. Haydn

PY - 2018/5

Y1 - 2018/5

N2 - Long-acting β2-agonists (LABAs) such as formoterol and salmeterol are used for prolonged bronchodilatation in asthma, usually in combination with inhaled corticosteroids (ICSs). Unexplained paradoxical asthma exacerbations and deaths have been associated with LABAs, particularly when used without ICS. LABAs clearly demonstrate effective bronchodilatation and steroid-sparing activity, but long-term treatment can lead to tolerance of their bronchodilator effects. There are also concerns with regard to the effects of LABAs on bronchial hyperresponsiveness (BHR), where long-term use is associated with increased BHR and loss of bronchoprotection. A complicating factor is that formoterol and salmeterol are both chiral compounds, usually administered as 50:50 racemic (rac-) mixtures of two enantiomers. The chiral nature of these compounds has been largely forgotten in the debate regarding LABA safety and effects on BHR, particularly that (S)-enantiomers of β2-agonists may be deleterious to asthma control. LABAs display enantioselective pharmacokinetics and pharmacodynamics. Biological plausibility of the deleterious effects of β2-agonists (S)-enantiomers is provided by in vitro and in vivo studies from the short-acting β2-agonist (SABA) salbutamol. Supportive clinical findings include the fact that patients in emergency departments who demonstrate a blunted response to salbutamol are more likely to benefit from (R)-salbutamol than rac-salbutamol, and resistance to salbutamol appears to be a contributory mechanism in rapid asthma deaths. More effort should therefore be applied to investigating potential enantiospecific effects of LABAs on safety, specifically bronchoprotection. Safety studies directly assessing the effects of LABA (S)-enantiomers on BHR are long overdue.

AB - Long-acting β2-agonists (LABAs) such as formoterol and salmeterol are used for prolonged bronchodilatation in asthma, usually in combination with inhaled corticosteroids (ICSs). Unexplained paradoxical asthma exacerbations and deaths have been associated with LABAs, particularly when used without ICS. LABAs clearly demonstrate effective bronchodilatation and steroid-sparing activity, but long-term treatment can lead to tolerance of their bronchodilator effects. There are also concerns with regard to the effects of LABAs on bronchial hyperresponsiveness (BHR), where long-term use is associated with increased BHR and loss of bronchoprotection. A complicating factor is that formoterol and salmeterol are both chiral compounds, usually administered as 50:50 racemic (rac-) mixtures of two enantiomers. The chiral nature of these compounds has been largely forgotten in the debate regarding LABA safety and effects on BHR, particularly that (S)-enantiomers of β2-agonists may be deleterious to asthma control. LABAs display enantioselective pharmacokinetics and pharmacodynamics. Biological plausibility of the deleterious effects of β2-agonists (S)-enantiomers is provided by in vitro and in vivo studies from the short-acting β2-agonist (SABA) salbutamol. Supportive clinical findings include the fact that patients in emergency departments who demonstrate a blunted response to salbutamol are more likely to benefit from (R)-salbutamol than rac-salbutamol, and resistance to salbutamol appears to be a contributory mechanism in rapid asthma deaths. More effort should therefore be applied to investigating potential enantiospecific effects of LABAs on safety, specifically bronchoprotection. Safety studies directly assessing the effects of LABA (S)-enantiomers on BHR are long overdue.

UR - http://www.scopus.com/inward/record.url?scp=85041313014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041313014&partnerID=8YFLogxK

U2 - 10.1007/s40264-017-0631-1

DO - 10.1007/s40264-017-0631-1

M3 - Article

VL - 41

SP - 441

EP - 449

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 5

ER -

Jacobson GA, Raidal S, Hostrup M, Calzetta L, Wood-Baker R, Farber MO et al. Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed. Drug Safety. 2018 May;41(5):441-449. https://doi.org/10.1007/s40264-017-0631-1